Obesity is a major contributor to the epidemic of metabolic diseases including dyslipidemia, cardiovascular disease, and type II diabetes. Numerous studies suggest that increasing energy expenditure can effectively decrease body weight. However, no current therapeutic compounds safely or selectively activate energy expenditure. The endocrine hormone fibroblast growth factor 21 (FGF21) decreases body weight during obesity by increasing energy expenditure without affecting physical activity. Moreover, FGF21 potently decreases both fat and body mass in obese animals and human patients. However, the mechanism for FGF21-mediated increases in energy expenditure has not been identified. Work from our lab and others have demonstrated that FGF21 acts in the central nervous system to promote weight loss. In addition, several lines of evidence suggest that FGF21 requires intact signaling from the adipose-derived hormone, leptin, to elicit its full effects on driving weight loss. Finally, our preliminary data demonstrates that the obligate FGF21 co- receptor, ?-klotho, is expressed in the arcuate nucleus (ARC) and ventromedial hypothalamus (VMH), primary sites of leptin action in the brain, and that leptin activates signaling in ?-klotho-expressing cells in the VMH and ARC. Thus, we hypothesize that FGF21 signals, at least in part, to leptin-sensitive cells in the VMH and/or ARC to modulate energy expenditure. This proposal employs novel genetic mouse models, chemogenetic manipulation of neurons, and pharmacological approaches to investigate the crosstalk between FGF21 and leptin signaling in the central control of energy homeostasis. Through these studies we aim to identify novel therapeutic targets for the treatment of obesity and obesity-associated disorders.
The proposed research aims at understanding a novel hormonal pathway that regulates body weight and metabolic flexibility with the ultimate goal to develop new treatments for obesity and obesity-associated diseases. Specifically, this proposal examines endocrine crosstalk between leptin and FGF21 signaling and evaluates the contribution of leptin signaling in the energy expending effects of FGF21.
| Klingelhutz, Aloysius J; Gourronc, Francoise A; Chaly, Anna et al. (2018) Scaffold-free generation of uniform adipose spheroids for metabolism research and drug discovery. Sci Rep 8:523 |
| Zhang, Peng; Kuang, Henry; He, Yanlin et al. (2018) NRG1-Fc improves metabolic health via dual hepatic and central action. JCI Insight 3: |
| Cushing, Emily M; Chi, Xun; Sylvers, Kelli L et al. (2017) Angiopoietin-like 4 directs uptake of dietary fat away from adipose during fasting. Mol Metab 6:809-818 |
| Potthoff, Matthew J (2017) FGF21 and metabolic disease in 2016: A new frontier in FGF21 biology. Nat Rev Endocrinol 13:74-76 |
| BonDurant, Lucas D; Ameka, Magdalene; Naber, Meghan C et al. (2017) FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms. Cell Metab 25:935-944.e4 |
| Markan, Kathleen R; Naber, Meghan C; Small, Sarah M et al. (2017) FGF21 resistance is not mediated by downregulation of beta-klotho expression in white adipose tissue. Mol Metab 6:602-610 |
| von Holstein-Rathlou, Stephanie; BonDurant, Lucas D; Peltekian, Lila et al. (2016) FGF21 Mediates Endocrine Control of Simple Sugar Intake and Sweet Taste Preference by the Liver. Cell Metab 23:335-43 |
| Littlejohn, Nicole K; Keen, Henry L; Weidemann, Benjamin J et al. (2016) Suppression of Resting Metabolism by the Angiotensin AT2 Receptor. Cell Rep 16:1548-1560 |
| Markan, Kathleen R; Potthoff, Matthew J (2016) Metabolic fibroblast growth factors (FGFs): Mediators of energy homeostasis. Semin Cell Dev Biol 53:85-93 |
